HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rite Aid

This article was originally published in The Tan Sheet

Executive Summary

Same-store, front-end sales grew 8.5% in fiscal second quarter ended Aug. 26, spurred by lower prices on key items, weekly advertising circulars and expanded product categories, drug chain announces Oct. 10. Front-end sales, which constituted 41% of total sales for the quarter, are expected to further improve due to enhanced supplier relationships, Rite Aid maintains. The chain posted net sales of $3.44 bil. for the quarter but incurred a net loss of $456.5 mil. Of that total, $77.2 mil. was related to the decline in drugstore.com's common stock, with additional losses of $12.5 mil. and $24.1 mil. representing Rite Aid's share of the e-commerce site's losses in the second quarter and first half, respectively. Rite Aid acquired a 25.3% share in drugstore.com in June 1999 (1"The Tan Sheet" June 28, 1999, p. 7)

You may also be interested in...



Drugstore.com Becomes Exclusive Internet Provider Of GNC Products

Drugstore.com will become the exclusive online source for General Nutrition Centers branded products following a strategic alliance between the Internet retailer, GNC and the drug chain Rite Aid.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS133676

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel